A 3,4-methylenedioxypyrovaleron (MDPV) használatával kapcsolatos klinikai tapasztalatok öt hospitalizált paciens esete kapcsán.

Translated title of the contribution: [Clinical characteristics of 5 hospitalized 3,4-methylenedioxypyrovalerone (MDPV) users].

Kinga Farkas, Enikö Sirály, Erika Szily, Gábor Csukly, J. Réthelyi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A new illegal psychotropic substance appeared in Hungary during the first months of 2011. Acutely hospitalized patients with psychosis disclosed using a new type of designer drug, previously unknown to clinicians. As the new drug became better known, the cases with acute intoxication were often also transported to toxicology departments. In this study we summarize 5 short case studies that demonstrate the heterogeneous symptoms associated with MDPV abuse, and draw attention to the frequently occurring delusions, and the extended risk of intravenous substance use. Present case studies include patients with and without psychiatric history, regular and occasional users, intravenous and other routes of administration. In the short run antipsychotic therapy reduced the symptoms in all cases, but there is no clear therapeutic guideline for the treatment of patients having psychiatric problems associated with these drugs at the present time. The laboratory examination is unresolved as well. Mephedrone, MDPV and recent drugs have drawn attention to the problem of designer drugs again. This article examines the interaction of drug consumption trends and changes in law, apropos of the presented cases. This information can be helpful for the future treatment of MDPV or other designer drug users. Possible research and therapeutic implications are also discussed.

Original languageHungarian
Pages (from-to)431-439
Number of pages9
JournalPsychiatria Hungarica : A Magyar Pszichiátriai Társaság tudományos folyóirata
Volume28
Issue number4
Publication statusPublished - 2013

Fingerprint

Designer Drugs
Psychiatry
Pharmaceutical Preparations
Therapeutic Human Experimentation
Delusions
Hungary
Therapeutics
Drug Users
Drug Interactions
Psychotic Disorders
Toxicology
Antipsychotic Agents
Guidelines
3,4-methylenedioxypyrovalerone

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A 3,4-methylenedioxypyrovaleron (MDPV) használatával kapcsolatos klinikai tapasztalatok öt hospitalizált paciens esete kapcsán. / Farkas, Kinga; Sirály, Enikö; Szily, Erika; Csukly, Gábor; Réthelyi, J.

In: Psychiatria Hungarica : A Magyar Pszichiátriai Társaság tudományos folyóirata, Vol. 28, No. 4, 2013, p. 431-439.

Research output: Contribution to journalArticle

@article{0d6bc1904e744d9697627dc8f9169664,
title = "A 3,4-methylenedioxypyrovaleron (MDPV) haszn{\'a}lat{\'a}val kapcsolatos klinikai tapasztalatok {\"o}t hospitaliz{\'a}lt paciens esete kapcs{\'a}n.",
abstract = "A new illegal psychotropic substance appeared in Hungary during the first months of 2011. Acutely hospitalized patients with psychosis disclosed using a new type of designer drug, previously unknown to clinicians. As the new drug became better known, the cases with acute intoxication were often also transported to toxicology departments. In this study we summarize 5 short case studies that demonstrate the heterogeneous symptoms associated with MDPV abuse, and draw attention to the frequently occurring delusions, and the extended risk of intravenous substance use. Present case studies include patients with and without psychiatric history, regular and occasional users, intravenous and other routes of administration. In the short run antipsychotic therapy reduced the symptoms in all cases, but there is no clear therapeutic guideline for the treatment of patients having psychiatric problems associated with these drugs at the present time. The laboratory examination is unresolved as well. Mephedrone, MDPV and recent drugs have drawn attention to the problem of designer drugs again. This article examines the interaction of drug consumption trends and changes in law, apropos of the presented cases. This information can be helpful for the future treatment of MDPV or other designer drug users. Possible research and therapeutic implications are also discussed.",
author = "Kinga Farkas and Enik{\"o} Sir{\'a}ly and Erika Szily and G{\'a}bor Csukly and J. R{\'e}thelyi",
year = "2013",
language = "Hungarian",
volume = "28",
pages = "431--439",
journal = "Psychiatria Hungarica",
issn = "0237-7896",
publisher = "Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata",
number = "4",

}

TY - JOUR

T1 - A 3,4-methylenedioxypyrovaleron (MDPV) használatával kapcsolatos klinikai tapasztalatok öt hospitalizált paciens esete kapcsán.

AU - Farkas, Kinga

AU - Sirály, Enikö

AU - Szily, Erika

AU - Csukly, Gábor

AU - Réthelyi, J.

PY - 2013

Y1 - 2013

N2 - A new illegal psychotropic substance appeared in Hungary during the first months of 2011. Acutely hospitalized patients with psychosis disclosed using a new type of designer drug, previously unknown to clinicians. As the new drug became better known, the cases with acute intoxication were often also transported to toxicology departments. In this study we summarize 5 short case studies that demonstrate the heterogeneous symptoms associated with MDPV abuse, and draw attention to the frequently occurring delusions, and the extended risk of intravenous substance use. Present case studies include patients with and without psychiatric history, regular and occasional users, intravenous and other routes of administration. In the short run antipsychotic therapy reduced the symptoms in all cases, but there is no clear therapeutic guideline for the treatment of patients having psychiatric problems associated with these drugs at the present time. The laboratory examination is unresolved as well. Mephedrone, MDPV and recent drugs have drawn attention to the problem of designer drugs again. This article examines the interaction of drug consumption trends and changes in law, apropos of the presented cases. This information can be helpful for the future treatment of MDPV or other designer drug users. Possible research and therapeutic implications are also discussed.

AB - A new illegal psychotropic substance appeared in Hungary during the first months of 2011. Acutely hospitalized patients with psychosis disclosed using a new type of designer drug, previously unknown to clinicians. As the new drug became better known, the cases with acute intoxication were often also transported to toxicology departments. In this study we summarize 5 short case studies that demonstrate the heterogeneous symptoms associated with MDPV abuse, and draw attention to the frequently occurring delusions, and the extended risk of intravenous substance use. Present case studies include patients with and without psychiatric history, regular and occasional users, intravenous and other routes of administration. In the short run antipsychotic therapy reduced the symptoms in all cases, but there is no clear therapeutic guideline for the treatment of patients having psychiatric problems associated with these drugs at the present time. The laboratory examination is unresolved as well. Mephedrone, MDPV and recent drugs have drawn attention to the problem of designer drugs again. This article examines the interaction of drug consumption trends and changes in law, apropos of the presented cases. This information can be helpful for the future treatment of MDPV or other designer drug users. Possible research and therapeutic implications are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=84899699746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899699746&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 431

EP - 439

JO - Psychiatria Hungarica

JF - Psychiatria Hungarica

SN - 0237-7896

IS - 4

ER -